Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 39.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,695 shares of the biopharmaceutical company’s stock after buying an additional 7,544 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Ultragenyx Pharmaceutical were worth $1,123,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of RARE. International Assets Investment Management LLC lifted its position in Ultragenyx Pharmaceutical by 29,580.0% in the third quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 10,353 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 34.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,333 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 851 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Ultragenyx Pharmaceutical by 195.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 21,753 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 14,394 shares during the period. Pallas Capital Advisors LLC purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $598,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Ultragenyx Pharmaceutical by 81.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,726 shares of the biopharmaceutical company’s stock worth $985,000 after buying an additional 7,960 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. JPMorgan Chase & Co. reduced their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Canaccord Genuity Group raised their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Wells Fargo & Company upped their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Finally, Wedbush reissued a “neutral” rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.50.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $41.62 on Thursday. The stock’s 50 day moving average price is $42.96 and its 200 day moving average price is $49.24. The company has a market cap of $3.85 billion, a PE ratio of -6.56 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 1-year low of $37.02 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.